SEPTInvestingStart Free

CERO 424B3: SEC filing

CERO Therapeutics

Filed with the SEC on · accession 0001213900-26-079223

CERO filed a 424B3 (prospectus (offering)) with the SEC on Jul 17, 2026. The final terms of an offering of shares or bonds.

Summary of the filing

CERO Therapeutics entered into a second amended and restated promissory note with SRX Global Inc. for up to $2,085,200, bearing 10% interest and convertible into common stock at a discount to market price.

For details, click here →How to read a 424B3 →

Key details

Maximum loan amount under note$2.1M
Amount funded on July 14, 2026$672K
Interest rate$10
IssuerCERO Therapeutics Holdings, Inc.
LenderSRX Global Inc.

✦ Ask GOAX AI about this filing — what it means for CERO, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for CERO?

Click here

Frequently asked questions

What did CERO file with the SEC on Jul 17, 2026?

CERO filed a 424B3 (SEC filing). CERO Therapeutics entered into a second amended and restated promissory note with SRX Global Inc. for up to $2,085,200, bearing 10% interest and convertible into common stock at a discount to market price.

How do I read a 424B3?

The final terms of an offering of shares or bonds. Look at price, number of shares and the discount to the market price. Large offerings dilute existing shareholders.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 424B3 (prospectus (offering)): The final terms of an offering of shares or bonds.

Other CERO SEC filings

Get alerts when CERO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
CERO overviewCERO analysisCERO newsLatest SEC filings